IPP Bureau
WuXi Biologics wins HERA 2025 Award for outstanding ESG disclosure
By IPP Bureau - December 29, 2025
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
CPHI & PMEC India 2025 ignites pharma innovation and partnerships
By IPP Bureau - December 29, 2025
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
ENHERTU gains first-ever nod in China for metastatic breast cancer
By IPP Bureau - December 29, 2025
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Singlera Genomics partners with Pure Medical to bring early cancer detection to Europe
By IPP Bureau - December 29, 2025
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Govt cancels registration of popular cosmetic product over misleading claims
By IPP Bureau - December 29, 2025
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
US House passes Bill reauthorizing FDA rare disease incentive program
By IPP Bureau - December 29, 2025
Akums and Sharda University ink MoU to bridge industry–academia gap
By IPP Bureau - December 29, 2025
The primary goal of the collaboration is joint research into trending and next-generation molecules
Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist
By IPP Bureau - December 29, 2025
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Intas and IntegriMedical to launch India’s first needle-free injection system for IVF and gynaecology
By IPP Bureau - December 29, 2025
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules
By IPP Bureau - December 28, 2025
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Zota Health Care raises Rs 350 crores through QIP issue
By IPP Bureau - December 28, 2025
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
InnoCare Pharma gets green light for Phase II trial of oral lupus drug
By IPP Bureau - December 27, 2025
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Ginkgo Bioworks teams with Carnegie Mellon on cancer detection program
By IPP Bureau - December 27, 2025
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
FDA setback for Sanofi’s Tolebrutinib in progressive MS
By IPP Bureau - December 27, 2025
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Health Minister Nadda to launch Indian Pharmacopoeia 2026 in the first week of Jan. 2026
By IPP Bureau - December 27, 2025
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
